Alkor Bio Group informs you about the release of 17 new allergens  and mixes of allergens for the «AllergoEIA-specific IgE» kit.

Microarrays    Tecan journal 1/2014   

Alkor Bio has developed a rapid and accurate microarray-based diagnostic assay for cystic fibrosis using Tecan’s HS 400™ Pro Hybridization Station and PowerScanner™, allowing one technician to screen 10 patients for 25 cystic fibrosis mutations in under seven hours.

Alkor Bio Group, one of the leading Russian developers and manufacturers of laboratory ELISA kits, started producing local anesthetics allergens for the kit AllergoEIA-specific IgE. Early February Alkor Bio Group has issued 13 new allergens, including local anesthetics allergens Ultracaine, Lidocaine, Benzocaine, Novocaine.

Sequoia genetics has received European CE Mark approval for next-generation sequencing solution for diagnostics of inherited diseases in newborns. The company got official notification from MediMark Europe at the end of 2013. Thus the solution named VariFind Neonatal assay is approved for in vitro diagnostics in European Economic Area.

In January 2014 Sequoia genetics (Saint-Petersburg, Russia) announced that the development of diagnostic solution intended for diagnostics of inherited diseases in newborns based on the next-generation sequencing (NGS) technology has been completed. The solution named VariFind Neonatal assay based on Ion PGM (Life Technologies, US) sequencing platform and consists of reagents kits, protocols and specialized software.

On October, 7-11, Alkor Bio Group of Companies has been assessed for compliance with the International standards ISO 9001 and ISO 13485.